A-Synuclein

Cellular and Molecular Events Leading to Paraquat-Induced Apoptosis: Mechanistic Insights into Parkinson’s Disease Pathophysiology

A-Synuclein, Parkinson's Disease, Pesticides /

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the cardinal features of tremor, bradykinesia, rigidity, and postural instability, in addition to other non-motor symptoms. Pathologically, PD is attributed to the loss of dopaminergic neurons in the substantia nigra pars compacta, with the hallmark of the presence of intracellular protein aggregates of α-synuclein in […]

Cellular and Molecular Events Leading to Paraquat-Induced Apoptosis: Mechanistic Insights into Parkinson’s Disease Pathophysiology Read More »

Bacteria-Derived Protein Aggregates Contribute to the Disruption of Host Proteostasis

A-Synuclein, Butyrate, Parkinson's Disease, Short Chain Fatty Acids /

Neurodegenerative protein conformational diseases are characterized by misfolding and aggregation of metastable proteins encoded within the host genome. The host is also home to thousands of proteins encoded within exogenous genomes harbored by bacteria, fungi, and viruses. Yet, their contributions to host protein-folding homeostasis, or proteostasis, remain elusive. Recent studies, including our previous work, suggest

Bacteria-Derived Protein Aggregates Contribute to the Disruption of Host Proteostasis Read More »

Alpha-synuclein as a Potential Biomarker for Parkinson’s Disease and Other
Synucleinopathies: Gaps, Challenges, and Opportunities

A-Synuclein, Biomarkers /

Parkinson’s disease (PD), the second most common progressive neurodegenerative disease,develops and progresses for 10-15 years before the clinical diagnostic symptoms of thedisease are manifested. Furthermore, several aspects of PD pathology overlap with otherneurodegenerative diseases (NDDs) linked to alpha-synuclein aggregation, also calledsynucleinopathies. Therefore, there is an urgent need to discover and validate earlydiagnostic and prognostic markersthat

Alpha-synuclein as a Potential Biomarker for Parkinson’s Disease and Other
Synucleinopathies: Gaps, Challenges, and Opportunities Read More »

Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats

A-Synuclein, Gut Permeability / Leaky Gut, Gut-Brain axis, Parkinson's Disease /

The cellular hallmarks of Parkinson’s disease (PD) are the loss of nigral dopaminergic neurons and the formation of α-synuclein-enriched Lewy bodies and Lewy neurites in the remaining neurons. Based on the topographic distribution of Lewy bodies established after autopsy of brains from PD patients, Braak and coworkers hypothesized that Lewy pathology primes in the enteric

Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats Read More »

Hydrogen Sulfide Produced by Gut Bacteria May Induce Parkinson’s Disease

A-Synuclein, Gut Microbiota, Probiotics, Prebiotics and Symbiotics /

Several bacterial species can generate hydrogen sulfide (H2S). Study evidence favors the view that the microbiome of the colon harbors increased amounts of H2S producing bacteria in Parkinson’s disease. Additionally, H2S can easily penetrate cell membranes and enter the cell interior. In the cells, excessive amounts of H2S can potentially release cytochrome c protein from

Hydrogen Sulfide Produced by Gut Bacteria May Induce Parkinson’s Disease Read More »

Relationships of Nutritional Factors and Agrochemical Exposure with Parkinson’s Disease in the Province of Brescia, Italy

A-Synuclein, Diet and Exercise, Gut Dysbiosis, Parkinson's Disease /

Environmental exposures to agrochemicals and nutritional factors may be associated with Parkinson’s Disease (PD). None of the studies to date has examined the combined effects of diet and agricultural chemical exposure together. To address these research gaps, we aimed to assess the association of nutritional factors and agrochemical exposure with the risk of PD. A

Relationships of Nutritional Factors and Agrochemical Exposure with Parkinson’s Disease in the Province of Brescia, Italy Read More »

Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Parkinson Disease Patients

A-Synuclein, Butyrate, Probiotics, Prebiotics and Symbiotics, Short Chain Fatty Acids /

We are grateful for the comment on our study.1 We are pleased to know that short chain fatty acids (SCFA), especially butyrate, in the intestine could stimulate the colonization of curli-producing Escherichia coli (E. coli). Curli are functional amyloids produced by gut microbes and act as cross-beta-sheet amyloid polymers to assist bacterial cells in binding to

Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Parkinson Disease Patients Read More »

Exploiting Caenorhabditis elegans to discover human gut microbiota-mediated intervention strategies in protein conformational diseases

A-Synuclein, Biomarkers, Butyrate, Gut Dysbiosis, Probiotics, Prebiotics and Symbiotics /

Age-dependent protein-conformational diseases (PCDs), such as Alzheimer’s disease (AD), Parkinson’s disease (PD), or amyotrophic lateral sclerosis (ALS), are characterized by misfolding and aggregation of metastable proteins present within the proteome of the affected individual. Recent evidence supports the notion that bacteria and bacterial products may be affecting the stability of these culprit host proteins and

Exploiting Caenorhabditis elegans to discover human gut microbiota-mediated intervention strategies in protein conformational diseases Read More »

ORAL BUTYRATE AND MICROBIOTA-TARGETED TREATMENTS FOR PARKINSON’S
DISEASE: EFFICACY STUDIES IN TRANSGENIC MICE.

A-Synuclein, Biomarkers, Butyrate, Gut Microbiota, Gut-Brain axis, Pre-PD, Probiotics, Prebiotics and Symbiotics /

Current pharmacological treatments for Parkinson’s disease (PD) provide relief for motorsymptoms but fail to alleviate prevalent non-motor symptoms (NMS)- such as gastrointestinal(GI) dysfunction which often occurs before the development of motor symptoms. Strategies toslow the progression of PD have been proposed, but so far none has proven successful. PDpatients display changes in gut microbiome composition

ORAL BUTYRATE AND MICROBIOTA-TARGETED TREATMENTS FOR PARKINSON’S
DISEASE: EFFICACY STUDIES IN TRANSGENIC MICE. Read More »

Probiotic Bacillus subtilis
Protects against a-Synuclein
Aggregation in C. elegans

A-Synuclein, Butyrate, Gut Dysbiosis, Probiotics, Prebiotics and Symbiotics /

Recent discoveries have implicated the gut microbiome in the progression and severity of Parkinson’s disease; however, how gut bacteria affect such neurodegenerative disorders remains unclear. Here, we report that the Bacillus subtilis probiotic strain PXN21 inhibits a-synuclein aggregation and clears preformed aggregates in an established Caenorhabditis elegans model of synucleinopathy. This protection is seen in

Probiotic Bacillus subtilis
Protects against a-Synuclein
Aggregation in C. elegans Read More »